Asim Pasha
Common condition seen in older men Risk factors 1-age: Around 50% of 50-year-old men will have evidence of BPH and 30% will have symptoms. Around 80% of 80-year-old men have evidence of BPH 2-ethnicity: black > white > Asian
Family history and genetic factors. Diet is possibly a risk factor. Exposure to the metal cadmium
lower urinary tract symptoms (LUTS) voiding symptoms (obstructive): weak or intermittent urinary flow, straining, hesitancy, terminal dribbling and incomplete emptying storage symptoms (irritative) urgency, frequency, urgency, incontinence and nocturia post-micturition: dribbling complications: urinary tract infection, retention, obstructive uropathy
>70 yrs with LUTS IPSS >7 i.e. moderate or severe LUTS Flow rate<12ml/s Prostrate volume >30cc Post void residual volume > 100mls
LUTS->assessment->PSA high ->refer exam/urine RE concern PSA haematuria U&E high palpable bladder recurrent uti abn. Cytology severe symp. LUTS->assessment-> bothersome->no-> RF prog exam/urine symp. yes LS + 5ARI PSA ->yes->RF prog ->yes->LS 5 ARI/AB3-6m ->no ->LS AB6-12w
watchful waiting medication: alpha-1 antagonists, 5 alpha-reductase inhibitors. The use of combination therapy was supported by the Medical Therapy Of Prostatic Symptoms (MTOPS) trial surgery: transurethral resection of prostate (TURP)
Alpha-1 antagonists e.g. tamsulosin, alfuzosin decrease smooth muscle tone (prostate and bladder) considered first-line, improve symptoms in around 70% of men adverse effects: dizziness, postural hypotension, dry mouth, depression
5 alpha-reductase inhibitors e.g. finasteride block the conversion of testosterone to dihydrotestosterone (DHT) Reduction in prostate volume - may slow disease progression. Symptoms may not improve for 6 months. May decrease PSA concentrations by up to 50% adverse effects: erectile dysfunction, reduced libido, ejaculation problems, gynaecomastia
Prostate cancer is the second most common cancer in adult males in the UK The most common malignant condition in men over 65 years. Risk factors increasing age Afro-Caribbean ethnicity
bladder outlet obstruction: hesitancy, urinary retention haematuria, haematospermia pain: back, perineal or testicular digital rectal examination: asymmetrical, hard, nodular enlargement with loss of median sulcus
important tumour marker but much controversy still exists regarding its usefulness as a screening tool Age-adjusted upper limits for PSA were recommended by the PCRMP*: Age PSA level (ng/ml) years- 3.0 years- 4.0 > 70 years- 5.0
PSA levels may be raised by: benign prostatic hyperplasia (BPH) prostatitis and UTI (NICE recommend to postpone the PSA test for at least 1 month after treatment) ejaculation (ideally not in the previous 48 hours) vigorous exercise (ideally not in the previous 48 hours) urinary retention instrumentation of the urinary tract whether digital rectal examination
Localised prostate cancer (T1/T2) Treatment depends on life expectancy and patient choice. Options include: conservative: active monitoring & watchful waiting radical prostatectomy radiotherapy: external beam and brachytherapy
Localised advanced prostate cancer (T3/T4) Options include: hormonal therapy radical prostatectomy radiotherapy: external beam and brachytherapy
Metastatic prostate cancer disease - hormonal therapy Synthetic GnRH agonist e.g. Goserelin (Zoladex) cover initially with anti-androgen to prevent rise in testosterone Anti-androgen cyproterone acetate prevents DHT binding from intracytoplasmic protein complexes Orchidectomy
Gleason score grading system is based on the glandular architecture seen on histology following hollow needle biopsy The most prevalent and the second most prevalent pattern seen are added to obtain a Gleason score. The Gleason grade ranges from 1 to 5 meaning the Gleason score ranges from 2 to 10 (i.e. two values added) The higher the Gleason score the worse the prognosis
The Prostate Cancer Charity Helpline: Web: Provides support and information for patients and their families. Prostate Action Tel: Web: A national charity dealing with all prostate diseases, including prostate cancer. Macmillan Cancer Support Tel: Web: Provides information and support to anyone affected by cancer. Cancer Research UK Web: provides facts about cancer including treatment choices. The NHS Prostate Cancer Risk Management Programme Web: Provides information as to why there is no organised screening programme for prostate cancer but an informed choice programme instead. Other support groups See for a list of support groups for cancer patients.
Are you ready?- This is the beginning…..